Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048836 | 0.98 | SLC2A1 (0.41) | SLC2A1 | |
| SCHEMBL15270780 | 0.78 | SLC2A1 (0.48) | SLC2A1 | |
| SCHEMBL8425537 | 0.78 | SLC2A1 (0.48) | SLC2A1 | |
| SCHEMBL15271621 | 0.75 | SLC2A1 (0.46) | SLC2A1 | |
| SCHEMBL8425472 | 0.74 | SLC2A1 (0.46) | SLC2A1 | |
| SCHEMBL11853588 | 0.74 | SLC2A1 (0.46) | SLC2A1 | |
| SCHEMBL28545184 | 0.74 | SLC2A1 (0.46) | SLC2A1 | |
| SCHEMBL20059830 | 0.71 | SLC2A1 (0.43) | SLC2A1 | |
| SCHEMBL15270702 | 0.70 | — | — | |
| SCHEMBL11737212 | 0.69 | SLC2A1 (0.44) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114611-A1 | Functionalized alkyllithium formulations with improved thermal stability and processes for making the same | FMC CORPORATION | 2003-06-19 | — | — | US | claimed |
| US-20030114592-A1 | Processes for improving stability of living polymer chain ends | FMC CORPORATION | 2003-06-19 | — | — | US | claimed |
| WO-2000050478-A1 | NOVEL FORMULATIONS OF ALKYLLITHIUMS WITH IMPROVED THERMAL STABILITY, PROCESSES TO PRODUCE THESE FORMULATIONS AND PROCESSES FOR USING THE SAME TO IMPROVE STABILITY OF LIVING POLYMER CHAIN ENDS | FMC CORPORATION (US) | 2000-08-31 | — | — | WO | claimed |
| US-20030114611-A1 | Functionalized alkyllithium formulations with improved thermal stability and processes for making the same | FMC CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-20030114592-A1 | Processes for improving stability of living polymer chain ends | FMC CORPORATION | 2003-06-19 | — | — | US | disclosed |
| WO-2000050478-A1 | NOVEL FORMULATIONS OF ALKYLLITHIUMS WITH IMPROVED THERMAL STABILITY, PROCESSES TO PRODUCE THESE FORMULATIONS AND PROCESSES FOR USING THE SAME TO IMPROVE STABILITY OF LIVING POLYMER CHAIN ENDS | FMC CORPORATION (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114611-A1 | Functionalized alkyllithium formulations with improved thermal stability and processes for making the same | AAAS, AS3MT, APC | SLC2A1 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.